📰 MRK Latest News
Last Updated: 2026.04.13 21:47:44
Recent Headlines
Ifinatamab Deruxtecan Granted Priority Review in the U.S. for Adult Patients with Previously Treated Extensive-Stage Small Cell Lung Cancer who Experienced Disease Progression on or After Platinum-Based Chemotherapy
BusinessWire
2026-04-13 9:47 PM
Revolution Medicines: PDAC Data Wows Wall Street - Jury's Out On Further Upside
SeekingAlpha
2026-04-13 4:35 PM
Terns Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Terns Pharmaceuticals, Inc. - TERN
BusinessWire
2026-04-10 7:37 PM
Merck Begins Tender Offer to Acquire Terns Pharmaceuticals, Inc.
BusinessWire
2026-04-07 1:00 PM
Terns Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Terns Pharmaceuticals, Inc. - TERN
BusinessWire
2026-03-26 1:59 AM
Merck & Co., Inc. (MRK) M&A Call Transcript
SeekingAlpha
2026-03-25 3:45 PM
Merck & Co., Inc. (MRK) Terns Pharmaceuticals, Inc. - M&A Call - Slideshow
SeekingAlpha
2026-03-25 2:31 PM
Merck to Acquire Terns Pharmaceuticals, Inc., Expanding Its Hematology Pipeline With TERN-701, a Novel Candidate for Chronic Myeloid Leukemia (CML)
BusinessWire
2026-03-25 10:45 AM
Merck to Acquire Terns Pharmaceuticals, Inc., Expanding Its Hematology Pipeline With TERN-701, a Novel Candidate for Chronic Myeloid Leukemia (CML)
BusinessWire
2026-03-25 10:45 AM
KEYTRUDA® (pembrolizumab) Plus Paclitaxel With or Without Bevacizumab Significantly Improved Key Secondary Endpoint of Overall Survival (OS) Versus Paclitaxel With or Without Bevacizumab in Patients With Platinum-Resistant Recurrent Ovarian Cancer
BusinessWire
2026-02-27 3:15 PM
KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) Reduced Risk of Event-Free Survival Events by 47% and Risk of Death by 35% for Cisplatin-Eligible Patients with Muscle-Invasive Bladder Cancer When Given Before and After Surgery
BusinessWire
2026-02-27 3:00 PM
Tenax Therapeutics: Some Future Potential
SeekingAlpha
2026-02-26 7:07 PM
FDA Approves NUMELVI™ (atinvicitinib tablets) for Dogs from Merck Animal Health – The First and Only Second-Generation Janus Kinase (JAK) Inhibitor for the Control of Pruritus Associated with Allergic Dermatitis
BusinessWire
2026-02-25 9:30 PM
Merck Announces Late-Breaking Data from Three Phase 3 Trials Evaluating Doravirine/Islatravir (DOR/ISL), an Investigational, Once-Daily, Two-Drug Regimen for the Treatment of Adults Living with HIV-1 at CROI 2026
BusinessWire
2026-02-25 5:37 PM
MoonLake: Downgrade To Buy As Sonelokimab Still Has A BLA Shot On Goal
SeekingAlpha
2026-02-24 6:50 PM
🔮
Keep Stock Illuminati Free
100% independent. Zero paywalls. Zero subscriptions.
Your support keeps the data flowing.
Donate via PayPal
One-time or recurring — every dollar helps us add more data & features.